I agree with you about immune tolerance. Working on an immunotherapy study on ovarian cancer we were following Rosenberg's methodology for treating metastatic melanoma with tumor infiltrating t-cells (TIL). I came across some very iffy data suggesting clonality in t-cells isolated from our patients and that got me to wondering if there …
I agree with you about immune tolerance. Working on an immunotherapy study on ovarian cancer we were following Rosenberg's methodology for treating metastatic melanoma with tumor infiltrating t-cells (TIL). I came across some very iffy data suggesting clonality in t-cells isolated from our patients and that got me to wondering if there might not be a problem in trying to use t-cells comfortable with that site and hence not so eager to attack tumors originating there, i.e. site specific tolerance.
Wow that sounds like a subset topic--site specific immune tolerance --to discuss in the Immune Tolerance module. I imagine that now and in the future many of these fantastic Substack posts will be circulated or repurposed like small educational internet pamphlets, and it is helpful for them to be parsed apart. If organized that way maybe people will find you more specifically for input.
I understand that Dr. Pierre Kory was able to harvest material from his own Substack and thoughts generated by commentary for his new book on Ivermectin.
Someday maybe Substack will be searchable for concepts, words, and such. I saw that being called for by commenters in Meryl Nass's recent Substack focused on censorship last week raising concerns about Substack itself.
Good luck on your study. I am thinking there will be plenty of ovarian cancer to manage going forward.
Thanks but those observations are two decades old. Been retired that long. The primary on that project was too much influenced by Rosenberg to consider other options so my idea pretty well died on the vine
I agree with you about immune tolerance. Working on an immunotherapy study on ovarian cancer we were following Rosenberg's methodology for treating metastatic melanoma with tumor infiltrating t-cells (TIL). I came across some very iffy data suggesting clonality in t-cells isolated from our patients and that got me to wondering if there might not be a problem in trying to use t-cells comfortable with that site and hence not so eager to attack tumors originating there, i.e. site specific tolerance.
Wow that sounds like a subset topic--site specific immune tolerance --to discuss in the Immune Tolerance module. I imagine that now and in the future many of these fantastic Substack posts will be circulated or repurposed like small educational internet pamphlets, and it is helpful for them to be parsed apart. If organized that way maybe people will find you more specifically for input.
I understand that Dr. Pierre Kory was able to harvest material from his own Substack and thoughts generated by commentary for his new book on Ivermectin.
Someday maybe Substack will be searchable for concepts, words, and such. I saw that being called for by commenters in Meryl Nass's recent Substack focused on censorship last week raising concerns about Substack itself.
Good luck on your study. I am thinking there will be plenty of ovarian cancer to manage going forward.
Thanks but those observations are two decades old. Been retired that long. The primary on that project was too much influenced by Rosenberg to consider other options so my idea pretty well died on the vine